Table 1.
General population characteristics (n = 110).
| Patient Characteristics | Statistics |
|---|---|
| Age (mean, standard deviation) | 81.7 ± 6 |
| Male (n, %) Female (n, %) |
42 (38.2%) 68 (61.8%) |
| Weight (mean, standard deviation) | 73.49 ± 14.6 |
| Kidney function (n = 108) a | |
| Serum creatinine (µmol/L) (mean, standard deviation) |
101.1 ± 78.6 |
| Creatinine clearance (mL/min) (mean, standard deviation) |
55.8 ± 20.6 |
| No CKD (n, %) | 7 (6.5%) |
| Mild CKD: creatinine clearance between 60 and 90 mL/min (n, %) | 35 (32.4%) |
| Moderate CKD: creatinine clearance between 30 and 60 mL/min (n, %) | 55 (50.9%) |
| Severe CKD: creatinine clearance < 30 mL/min (n, %) | 11 (10.2%) |
| Frailty (n = 109) b | |
| Fried score (median, (Q25, Q75)) |
3 [2; 4] |
| Fried frailty criteria b | |
| Weight loss (n, %) | 22 (20.0%) |
| Feelings of exhaustion (n, %) | 57 (52.3%) |
| Muscle weakness (n, %) | 90 (82.6%) |
| Reduced walking speed (n, %) | 64 (58.7%) |
| Sedentary lifestyle (n, %) | 87 (79.1%) |
| Falls (n = 107) c | |
| Yes (n, %) | 36 (33.6%) |
| Treatment | |
| Number of medications prescribed d (mean, standard deviation) | 8.2 ± 3.3 |
| Number of glucose-lowering medication (mean, standard deviation) | 1.4 ± 1.0 |
| Therapeutic strategy (n, %) | N (%) |
| Lifestyle changes only | 20 (18.2%) |
| Oral glucose-lowering drug only | 51 (46.4%) |
| 1 OGLD | 32 (29.1%) |
| 2 OGLDs | 17 (15.5%) |
| ≥3 OGLDs | 2 (1.8%) |
| Oral glucose-lowering drug + Insulin | 17 (15.5%) |
| 1 OGLD + Insulin | 9 (8.2%) |
| ≥ 2 OGLDs + Insulin | 8 (7.3%) |
| Insulin only | 22 (20.0%) |
Legend: CKD: chronic kidney disease; OGLD: Oral glucose-lowering drugs. a n = 2 for kidney function; b n = 1 for frailty score, feeling of exhaustion, reduced walking speed, muscle weakness; c n = 3 for falls; d n = 2 for number of prescribed medications.